Clinical trials: Anticoagulation With Apixaban
Venous Thromboembolism, Active Cancer
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
This prospective, multicenter, randomized, open-label, blinded-endpoint trial aims to compare the clinical efficacy and safety of edoxaban-based treatment versus apixaban-based treatment in patients with cancer-associated venous…
- Trial name
- NEXT-CAT (NCT07852637)
- Testing
- edoxaban, Apixaban
- Where
- 12 sites in South Korea
- Volunteers
- 2,300 people
- Sponsor
- Samsung Medical Center
COVID-19
Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care
The purpose of the study is to describe the safety and efficacy outcomes of a cohort of ICU patients with severe COVID-19 respiratory disease treated with therapeutic dose Apixaban for COVID-19 at a tertiary public health care…
- Trial name
- ECRU (NCT05088928)
- Testing
- Apixaban, Rivaroxaban
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- Scotmann Pharmaceuticals
Atrial Fibrillation
Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Atrial fibrillation (AF) is the most common sustained abnormal rhythm of the heart, affects an estimated 2.5 to 5 million individuals in the US, and can lead to stroke, heart failure, and premature death.
- Trial name
- REACT COM (NCT01706146)
- Testing
- Non-coumadin Oral Anticoagulant
- Where
- 3 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- Northwestern University
Endstage Renal Disease, Direct Oral Anticoagulants (DOACs)
Effect of Apiban Therapy on AVF Maturation in ESRD Patients
End-stage renal disease (ESRD) is a growing global health burden, and the creation of a native arteriovenous fistula (AVF) is the gold standard for vascular access in patients requiring hemodialysis [1].
- Conditions
- Endstage Renal Disease, Direct Oral Anticoagulants (DOACs), Arteriovenous Fistula, Arteriovenous Fistula Occlusion
- Trial name
- NCT07559942
- Testing
- Apixaban
- Where
- Pakistan
- Volunteers
- 190 people
- Sponsor
- Combined military hospital lahore
Deep Vein Thrombosis, Pulmonary Embolism
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-VTE study is a nationwide cluster randomized cross-over study comparing efficacy and safety of…
- Trial name
- DANNOAC-VTE (NCT03129555)
- Testing
- Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet
- Where
- 26 sites in Denmark
- Volunteers
- 5,000 people
- Sponsor
- Herlev and Gentofte Hospital
Cerebral Hemorrhage, Atrial Fibrillation
Apixaban After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation
There is a marked lack of evidence on the optimal prevention of ischaemic stroke in patients with atrial fibrillation and a recent intracerebral haemorrhage (ICH) during treatment with oral anticoagulation.
- Trial name
- APACHE-AF (NCT02565693)
- Testing
- Apixaban, Aspirin, Carbasalate calcium
- Where
- 16 sites in Netherlands
- Volunteers
- 101 people
- Sponsor
- UMC Utrecht
Anticoagulation
Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France
The present study will be conducted to assess the following research questions in real-life conditions in France: What are the patient and disease characteristics, comorbidities and treatment history in NVAF patients initiating a…
- Trial name
- NCT02714855
- Testing
- Apixaban
- Where
- France
- Volunteers
- 2,081 people
- Sponsor
- Bristol-Myers Squibb
Chronic Kidney Diseases, Atrial Fibrillation
Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation
Objective: To study the efficacy and safety of apixaban as stroke prophylaxis in patients with chronic kidney disease (CKD) stage 5 and atrial fibrillation (AF) with or without dialysis treatment.
- Conditions
- Chronic Kidney Diseases, Atrial Fibrillation, Stroke, Intracerebral Hemorrhage
- Trial name
- SACK (NCT05679024)
- Testing
- Apixaban 2.5 milligram Oral Tablet
- Where
- 34 sites in Finland, Iceland and 2 more
- Volunteers
- 1,400 people
- Sponsor
- Region Stockholm
Neoplasms, Embolism
Anticoagulation in Patients With Venous Thromboembolism and Cancer
This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns,healthcare resource utilisation (HCRU), direct and indirect…
- Trial name
- VICTORIE (NCT04618913)
- Testing
- Apixaban, Rivaroxaban, Edoxaban
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Pfizer
Atrial Fibrillation
Non-Interventional Study Describing Direct Costs Related to Anti-coagulation Treatment
To describe the direct costs related to warfarin/apixaban treatment
- Trial name
- NCT04435769
- Where
- Czechia
- Volunteers
- 109 people
- Sponsor
- Pfizer
Deep Vein Thrombosis, Pulmonary Embolism
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)
The purpose of this study is to learn whether apixaban can prevent the blood clots in the leg (deep vein thrombosis) and lung (pulmonary embolism) that sometimes occur after hip replacement surgery and to learn how apixaban…
- Trial name
- NCT00423319
- Testing
- Enoxaparin, Apixaban
- Where
- 143 sites in United States, Argentina and 19 more
- Volunteers
- 5,407 people
- Sponsor
- Bristol-Myers Squibb
Lymphoma, Acute Lymphoblastic Leukemia
A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase
The purpose of this study is to compare the effect of a blood thinning drug called Apixaban versus no administration of a blood thinning drug, in preventing blood clots in children with leukemia or lymphoma.
- Trial name
- NCT02369653
- Testing
- Apixaban, No systemic anticoagulant prophylaxis
- Where
- 96 sites in United States, Australia and 10 more
- Volunteers
- 512 people
- Sponsor
- Bristol-Myers Squibb
Short Bowel Syndrome, Anticoagulation
Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition
Short bowel syndrome (SBS) is defined as a loss of function of the small intestine resulting in a malabsorptive disorder. In SBS, oral drug absorption may be altered due to extensive intestinal resection.
- Trial name
- ABSORB (NCT04344717)
- Testing
- Apixaban single dose, Apixaban steady-state
- Where
- Belgium
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Atrial Fibrillation, Peritoneal Dialysis Complication
Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation: a Prospective, Randomised, Open-label, Blinded End-point Trial (APIDP2)
Introduction: Several randomised controlled trials have demonstrated that novel oral anticoagulants (NOACs) are safer compared to vitamin K antagonists for the management of non valvular atrial fibrillation (NVAF) to prevent…
- Trial name
- APIDP2 (NCT06045858)
- Testing
- Anticoagulation Agents
- Volunteers
- 178 people
- Sponsor
- University Hospital, Caen
Venous Thromboembolic Disease, Kidney Failure, Chronic
Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data
Patients with end stage renal disease (ESRD) are at significantly increased risk of thrombosis and bleeding relative to those with normal renal function which makes anticoagulation particularly challenging.
- Trial name
- NCT04818151
- Testing
- Warfarin, Apixaban
- Where
- United States
- Volunteers
- 14,914 people
- Sponsor
- Johns Hopkins University
Vaso-occlusive Crisis, Reduction in Hospitalizations
Apixaban in Patients With Sickle Cell Disease
In patients with SCD, the use of low dose anticoagulation as an outpatient may lead to a significant decrease in morbidity and as a result, decrease healthcare utilization and costs.
- Conditions
- Vaso-occlusive Crisis, Reduction in Hospitalizations, Sickle Cell Disease
- Trial name
- NCT02179177
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Nirmish Shah
Anticoagulation
A Nationwide Registry Study of Patients With Nonvalvular Atrial Fibrillation Initiating Oral Anticoagulation Therapies In The Early Period Following Apixaban Marketing In Denmark
The purpose of this study is to describe the characteristics of patients treated with different OATs and whether these characteristics differ between treatments.
- Trial name
- NCT02591732
- Where
- Denmark
- Volunteers
- 52,178 people
- Sponsor
- Bristol-Myers Squibb
VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery
A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery
The primary purpose of Part 1 in this study is to assess the safety and tolerability of JNJ-64179375 for each dose level for dose escalation and any bleeding events (the composite of major, clinically relevant non-major, and…
- Trial name
- TEXT-TKR (NCT03251482)
- Testing
- JNJ-64179375 0.3 mg/kg, JNJ-64179375 0.6 mg/kg, JNJ-64179375 1.2 mg/kg
- Where
- 103 sites in United States, Argentina and 14 more
- Volunteers
- 308 people
- Sponsor
- Janssen Research & Development, LLC
Anticoagulation With Apixaban
Apixaban Validation Study - Additional Study on Fresh Samples
The objective is to demonstrate the performances of STA® - Apixaban Calibrator \& STA® - Apixaban Control used in combination with STA® - Liquid Anti-Xa to measure apixaban concentration in plasma.
- Trial name
- NCT03073265
- Testing
- STA-Apixaban Calibrator & Control
- Where
- 2 sites in United States
- Volunteers
- 109 people
- Sponsor
- Diagnostica Stago
Bleeding
A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban
The purpose of this stuy is to evaluate the ability of Andexanet Alfa to reverse the anticoagulation effect of Apixaban.
- Trial name
- NCT02207725
- Testing
- Andexanet
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals